|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RSAD1 |
Gene summary for RSAD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RSAD1 | Gene ID | 55316 |
| Gene name | radical S-adenosyl methionine domain containing 1 | |
| Gene Alias | HemW | |
| Cytomap | 17q21.33 | |
| Gene Type | protein-coding | GO ID | GO:0006725 | UniProtAcc | Q9HA92 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55316 | RSAD1 | LZE4T | Human | Esophagus | ESCC | 3.35e-03 | 1.38e-01 | 0.0811 |
| 55316 | RSAD1 | LZE22T | Human | Esophagus | ESCC | 1.18e-03 | 3.80e-01 | 0.068 |
| 55316 | RSAD1 | LZE24T | Human | Esophagus | ESCC | 2.83e-16 | 4.44e-01 | 0.0596 |
| 55316 | RSAD1 | P2T-E | Human | Esophagus | ESCC | 3.31e-15 | 3.31e-01 | 0.1177 |
| 55316 | RSAD1 | P4T-E | Human | Esophagus | ESCC | 3.32e-10 | 3.52e-01 | 0.1323 |
| 55316 | RSAD1 | P5T-E | Human | Esophagus | ESCC | 3.80e-13 | 2.14e-01 | 0.1327 |
| 55316 | RSAD1 | P8T-E | Human | Esophagus | ESCC | 6.33e-08 | 1.31e-01 | 0.0889 |
| 55316 | RSAD1 | P9T-E | Human | Esophagus | ESCC | 1.74e-07 | 9.37e-02 | 0.1131 |
| 55316 | RSAD1 | P10T-E | Human | Esophagus | ESCC | 5.91e-15 | 3.36e-01 | 0.116 |
| 55316 | RSAD1 | P11T-E | Human | Esophagus | ESCC | 2.97e-17 | 5.50e-01 | 0.1426 |
| 55316 | RSAD1 | P12T-E | Human | Esophagus | ESCC | 1.24e-23 | 5.34e-01 | 0.1122 |
| 55316 | RSAD1 | P15T-E | Human | Esophagus | ESCC | 3.35e-10 | 2.55e-01 | 0.1149 |
| 55316 | RSAD1 | P16T-E | Human | Esophagus | ESCC | 6.62e-18 | 3.86e-01 | 0.1153 |
| 55316 | RSAD1 | P17T-E | Human | Esophagus | ESCC | 2.79e-06 | 2.50e-01 | 0.1278 |
| 55316 | RSAD1 | P19T-E | Human | Esophagus | ESCC | 6.78e-03 | 3.99e-01 | 0.1662 |
| 55316 | RSAD1 | P20T-E | Human | Esophagus | ESCC | 2.55e-10 | 2.95e-01 | 0.1124 |
| 55316 | RSAD1 | P21T-E | Human | Esophagus | ESCC | 4.67e-13 | 2.55e-01 | 0.1617 |
| 55316 | RSAD1 | P22T-E | Human | Esophagus | ESCC | 9.10e-14 | 1.63e-01 | 0.1236 |
| 55316 | RSAD1 | P23T-E | Human | Esophagus | ESCC | 2.69e-16 | 4.33e-01 | 0.108 |
| 55316 | RSAD1 | P24T-E | Human | Esophagus | ESCC | 1.34e-12 | 2.44e-01 | 0.1287 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00067791 | Esophagus | ESCC | porphyrin-containing compound biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
| GO:00330141 | Esophagus | ESCC | tetrapyrrole biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
| GO:00330132 | Esophagus | ESCC | tetrapyrrole metabolic process | 37/8552 | 59/18723 | 6.23e-03 | 2.29e-02 | 37 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RSAD1 | SNV | Missense_Mutation | c.547N>A | p.Glu183Lys | p.E183K | Q9HA92 | protein_coding | tolerated(0.63) | benign(0.021) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RSAD1 | SNV | Missense_Mutation | rs373296180 | c.535N>T | p.Arg179Trp | p.R179W | Q9HA92 | protein_coding | deleterious(0.04) | possibly_damaging(0.625) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RSAD1 | SNV | Missense_Mutation | c.340N>C | p.Glu114Gln | p.E114Q | Q9HA92 | protein_coding | deleterious(0.02) | benign(0.342) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RSAD1 | SNV | Missense_Mutation | novel | c.864N>C | p.Trp288Cys | p.W288C | Q9HA92 | protein_coding | deleterious(0.02) | benign(0.258) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| RSAD1 | insertion | Frame_Shift_Ins | novel | c.533_534insCCCTGACTGGG | p.Arg179ProfsTer20 | p.R179Pfs*20 | Q9HA92 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RSAD1 | insertion | Nonsense_Mutation | novel | c.708_709insAGAGAAACAAATATGGACAAATGGTGAATCAAGATGAAGGTTTTT | p.Leu236_Phe237insArgGluThrAsnMetAspLysTrpTerIleLysMetLysValPhe | p.L236_F237insRETNMDKW*IKMKVF | Q9HA92 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| RSAD1 | SNV | Missense_Mutation | novel | c.305G>T | p.Ser102Ile | p.S102I | Q9HA92 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| RSAD1 | SNV | Missense_Mutation | rs144457267 | c.694N>T | p.Arg232Trp | p.R232W | Q9HA92 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RSAD1 | SNV | Missense_Mutation | rs375119650 | c.1028N>A | p.Arg343His | p.R343H | Q9HA92 | protein_coding | deleterious(0.04) | benign(0.379) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| RSAD1 | SNV | Missense_Mutation | c.1230N>T | p.Trp410Cys | p.W410C | Q9HA92 | protein_coding | tolerated(0.19) | probably_damaging(0.998) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |